4 articles
A new mouse study shows fisetin senolytic treatment reverses age-related endothelial dysfunction by eliminating senescent cells and reducing the SASP factor CXCL12.
A Phase 2 pilot trial investigates whether the natural senolytic compound fisetin can reduce dysfunction and complications in COVID-19 patients.
Fisetin is emerging as a top senolytic candidate, clearing senescent cells linked to aging — and strawberries are its richest dietary source.
Intermittent fisetin dosing in old mice reduced frailty and boosted grip strength, matching results from genetic and synthetic senolytic approaches.
